Phase Iii Trials - Pharma

Relevant Publications

Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study.

Issue Release: 2024

Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint.

Issue Release: 2024

Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.

Issue Release: 2024

Comparison of the efficacy, safety, and tolerability of the new FDC telmisartan + bisoprolol with comparator telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: The double-blind, multicentric, phase-III clinical study.

Issue Release: 2024

Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC).

Issue Release: 2024

Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and cost-utility analysis.

Issue Release: 2024

Breast cancer epigenetics: current and evolving treatment.

Issue Release: 2024

Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study.

Issue Release: 2024

Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.

Issue Release: 2024

Re-examining the factor structure of the Insomnia Severity Index (ISI) and defining the meaningful within-individual change (MWIC) for subjects with insomnia disorder in two phase III clinical trials of the efficacy of lemborexant.

Issue Release: 2024

Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring.

Issue Release: 2024

Factors associated with a placebo effect in Parkinson\'s disease in clinical trials: a meta-analysis.

Issue Release: 2024

Pooling Alzheimer\'s disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action.

Issue Release: 2024

Management of Locally Advanced Rectal Cancer: ASCO Guideline.

Issue Release: 2024

Ongoing randomized clinical trials on HSCT in multiple sclerosis.

Issue Release: 2024

Characterization of the clinically approved MRI tracer resotran for magnetic particle imaging in a comparison study.

Issue Release: 2024

Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study.

Issue Release: 2024

Phase I DAVIO Trial: EYP-1901 Bioerodible, Sustained-Delivery Vorolanib Insert in Patients With Wet Age-Related Macular Degeneration.

Issue Release: 2024

Efficacy and safety of personalized optimal PD-(L)1 combinations in advanced NSCLC: a network Meta-Analysis.

Issue Release: 2024

Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.

Issue Release: 2024

How Long Does the Approval Process Take?

What Are the Challenges in Managing Chronic Conditions?

Why is the Management of Chronic Conditions Important?

Why is Transitional Care Important in Pharma?

What Education and Training Do Pharmacists Need?

How Can Pharma Companies Improve Patient Education?

What is Medication Management?

What are the Phases of Clinical Trials?

What Role Does Regulatory Affairs Play?

What are Contract Research Organizations (CROs)?

Phase Iii Trials - Pharma

Relevant Publications

Partnered Content Networks

Relevant Topics